PMV Pharmaceuticals Reports Q3 2026 Results, $108.5M in Cash and Securities
PMV Pharmaceuticals reported a Q3 2026 net loss of $34.4M, with $108.5M in cash. It expects cash to last into Q1 2028. The company completed enrollment for its Phase 2 ovarian cancer trial and plans to submit a rezatapopt NDA in Q1 2027. Research and development expenses were $16.1M, with general and administrative expenses at $4.0M. The company appointed new board members and a chief commercial officer.
How this was made
The 30-second read
Why it matters
The disclosed data provides the first public view of rezatapopt's efficacy and the company's cash position, informing valuation and upcoming NDA expectations.
Market read
New trial data and cash runway are material for investors; the filing may trigger price movement.
What to watch
Potential competition in TP53 Y220C targeted therapies and upcoming NDA filing timeline.
Background
PMV Pharmaceuticals filed an 8‑K reporting Q3 2026 financials and Phase 2 trial outcomes.
Ticker impact
Q3 2026 results disclosed net loss, cash position, and positive Phase 2 trial data for rezatapopt.
potential modest upside as investors price in positive trial data, but pressure from sizable net loss.
Trial data is material for a biotech; cash runway supports continued development, while loss may limit short-term price.
Market effects
Phase 2 ovarian cancer data may lift peer biotech stocks in oncology.
Limited to US biotech sector.
Modest, confined to specialty pharma investors.
Counterpoint
The net loss and cash burn could outweigh trial optimism, prompting a sell-off.
Key entities
- companyPMV Pharmaceuticals
Biotech firm developing rezatapopt for TP53 Y220C ovarian cancer.
